Gossamer Bio, Inc. (GOSS)

Revance Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	455	205	206	205	854	701
Market Cap Growth	-6.10%	-0.34%	0.56%	-76.06%	21.87%	-26.45%
Enterprise Value	399	82	93	118	673	329
Last Close Price	2.00	0.90	0.91	2.17	11.31	9.67
PS Ratio	3.64	1.79	-	-	-	-
PB Ratio	-	6.95	3.28	16.94	7.03	2.19
P/TBV Ratio	-	6.95	3.28	16.94	7.03	2.19
EV/Sales Ratio	3.21	0.71	-	-	-	-
Debt / Equity Ratio	-32.45	6.88	3.39	18.69	1.53	0.57
Debt / FCF Ratio	22.32	-	-	-	-	-
Asset Turnover	0.46	0.37	-	-	-	-
Quick Ratio	5.49	6.66	5.75	5.19	8.16	13.27
Current Ratio	5.71	6.89	5.94	5.32	8.32	13.51
Return on Equity (ROE)	-500.57%	-122.54%	-480.50%	-343.53%	-105.85%	-72.30%
Return on Assets (ROA)	-12.68%	-11.94%	-37.17%	-44.34%	-30.58%	-27.25%
Return on Capital (ROIC)	-15.84%	-14.75%	-42.34%	-50.17%	-33.30%	-29.36%
Earnings Yield	-11.27%	-27.58%	-87.42%	-112.15%	-27.39%	-34.71%
FCF Yield	2.00%	-1.69%	-77.38%	-91.64%	-22.29%	-25.37%
Buyback Yield / Dilution	-22.21%	-48.23%	-80.46%	-13.00%	-9.24%	-25.16%

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q